← All trials
NCT03331562
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 27, 2017
- Primary completion
- May 15, 2019
- Completion date
- Dec 15, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 24
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- TGen Drug DevelopmentLead sponsor
- MerckCollaborator
- Stand Up To CancerCollaborator
- TGen Drug DevelopmentStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.